Načítá se...
Clinical Development of Immune Checkpoint Inhibitors
Recent progress in cancer immunotherapy has been remarkable. Most striking are the clinical development and approval of immunomodulators, also known as immune checkpoint inhibitors. These monoclonal antibodies (mAb) are directed to immune checkpoint molecules, which are expressed on immune cells and...
Uloženo v:
| Vydáno v: | Biomed Res Int |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Hindawi Publishing Corporation
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4486755/ https://ncbi.nlm.nih.gov/pubmed/26161407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/605478 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|